Alembic Pharmaceuticals Ltd has received tentative approval from the US Food and Drug Administration for brexpiprazole tablets in 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg strengths, according to an exchange filing.
The drug is a generic version of Otsuka Pharmaceutical Co Ltd's Rexulti tablets.
It is indicated as adjunctive therapy alongside antidepressants for the treatment of major depressive disorders and schizophrenia.
According to information from IQVIA, the drug's sales for the fiscal year that ended in December 2022 totaled about $1.6 billion.
Chhattisgarh: 'India Is Losing War Against Pakistan,' Says Congress Ex-MLA UD Minz
Bombay HC Contempt Case: 'It's My Fundamental Right To Speak,' Says Advocate Representing Disha Salian’s Father
WAVES 2025: PM Modi To Inaugurate Global Media Summit in Mumbai From May 1; 33 Nations To Attend, AR Rahman To Perform
Mumbai Crime News: House Help Steals Gold Worth ₹34.49 Lakh From Model Neha Malik’s Home In Andheri
The shares of the company traded 0.7% higher at ₹515.75 on NSE, at 09:15 IST.
